Telmisartan

동의어: Telmisartan, 144701-48-4, Micardis, Pritor, Kinzal, BIBR 277, Telmisartanum

Telmisartan is a non-peptide angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor subtype. It was developed by Boehringer Ingelheim and has been a cornerstone in the management of hypertension and cardiovascular risk reduction since its approval in the late 1990s. Unlike many other ARBs, telmisartan possesses a unique biphenyl carboxylic acid structure that confers high lipophilicity and a long duration of action.

Its molecular formula is C33H30N4O2, with a molecular weight of 514.62 g/mol. The compound is practically insoluble in water but freely soluble in DMSO and slightly soluble in ethanol. This solubility profile, along with its high melting point, makes it a stable and manageable API for solid dosage forms.

As a generic API, telmisartan is standardized to ≥99.0% purity (HPLC) and is widely used in the manufacture of immediate-release tablets, often in combination with hydrochlorothiazide or amlodipine. Its well-established efficacy and safety profile have made it a preferred choice for formulators targeting the global cardiovascular market.

Function & Mechanism

• Angiotensin II receptor blockade: Telmisartan selectively blocks the AT1 receptor, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II.
• Blood pressure reduction: By inhibiting AT1, it lowers systemic vascular resistance and reduces blood pressure without affecting heart rate.
• Cardiovascular protection: It may also provide end-organ protection, particularly in patients with diabetes or heart failure.
• Partial PPAR-γ agonism: Telmisartan exhibits unique partial agonist activity at PPAR-γ, which may contribute to improved insulin sensitivity and metabolic effects.

Source & Standardization

• Source: Synthetic chemical synthesis
• Manufacturing process: Multi-step organic synthesis followed by purification and crystallization
• Standardization: ≥99.0% (HPLC)
• Forms: White to off-white crystalline powder
• 응용 분야: API for antihypertensive tablets, fixed-dose combinations, and clinical research

Quality Specifications (QC Tests)

Bulk Supply & Documentation

• Monthly capacity: 5 metric tons
• 리드 타임: 3-5 business days (stock items)
• 문서: COA, MSDS, TDS, DMF available upon request
• 포장: 25 kg fiber drum with double polyethylene liner, or as per customer requirements

자주 묻는 질문

What is the minimum order quantity (MOQ)?

Our standard MOQ is 1 kg, but we can accommodate smaller quantities for research and development purposes.

Do you provide a Certificate of Analysis (COA) and samples?

Yes, we provide a COA for each batch and can offer samples for evaluation upon request.

What is the typical lead time?

Standard lead time is 3-5 business days after order confirmation, depending on quantity and destination.

Contact & Ordering Information

• Company: LyvBio Co., Ltd.
• Address: Room 5-0203, Courtyard 205, Lianhu District, Xi’an, Shaanxi, China
• Email: info@lyvbio.com
• Phone: +86-29-65816888

Learn more about our quality control and certifications, or send us your specification for a quotation.